SynAct Pharma AB

DB:8F8 Stock Report

Market Cap: €40.7m

SynAct Pharma Management

Management criteria checks 0/4

SynAct Pharma's CEO is Jeppe Ovlesen, appointed in Mar 2024, has a tenure of less than a year. directly owns 0.033% of the company’s shares, worth €13.61K. The average tenure of the management team and the board of directors is 1.4 years and 0.7 years respectively.

Key information

Jeppe Ovlesen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.03%
Management average tenure1.4yrs
Board average tenureless than a year

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jeppe Ovlesen's remuneration changed compared to SynAct Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 155m

Jun 30 2024n/an/a

-SEK 166m

Mar 31 2024n/an/a

-SEK 191m

Dec 31 2023n/an/a

-SEK 216m

Sep 30 2023n/an/a

-SEK 156m

Jun 30 2023n/an/a

-SEK 148m

Mar 31 2023n/an/a

-SEK 129m

Dec 31 2022SEK 4mSEK 3m

-SEK 99m

Sep 30 2022n/an/a

-SEK 95m

Jun 30 2022n/an/a

-SEK 89m

Mar 31 2022n/an/a

-SEK 78m

Dec 31 2021SEK 2mSEK 2m

-SEK 69m

Sep 30 2021n/an/a

-SEK 52m

Jun 30 2021n/an/a

-SEK 41m

Mar 31 2021n/an/a

-SEK 35m

Dec 31 2020SEK 2mSEK 2m

-SEK 27m

Sep 30 2020n/an/a

-SEK 29m

Jun 30 2020n/an/a

-SEK 24m

Mar 31 2020n/an/a

-SEK 23m

Dec 31 2019SEK 2mSEK 2m

-SEK 24m

Sep 30 2019n/an/a

-SEK 20m

Jun 30 2019n/an/a

-SEK 23m

Mar 31 2019n/an/a

-SEK 24m

Dec 31 2018SEK 2mSEK 2m

-SEK 23m

Sep 30 2018n/an/a

-SEK 23m

Jun 30 2018n/an/a

-SEK 19m

Mar 31 2018n/an/a

-SEK 15m

Dec 31 2017SEK 2mSEK 2m

-SEK 15m

Compensation vs Market: Insufficient data to establish whether Jeppe's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Jeppe's compensation has increased whilst the company is unprofitable.

CEO

Jeppe Ovlesen (62 yo)

less than a year

Tenure

SEK 3,656,000

Compensation

Mr. Jeppe Ovli Ovlesen, EE, MBA, serves CEO & Director of SynAct Pharma AB since March 20, 2024. He serves as Director at Cereno Scientific AB (publ) since November 07, 2023. He served as the Chief Execut...

Leadership Team

NamePositionTenureCompensationOwnership
Jeppe Ovlesen
CEO & Directorless than a yearSEK 3.66m0.033%
€ 13.6k
Bjorn Westberg
Chief Financial Officer1.4yrsno datano data
Thomas Boesen
Chief Operating Officer3.8yrsno data0.045%
€ 18.3k
James Knight
Chief Business Officer3.8yrsno datano data
Kristen Harting
Chief Medical Officerless than a yearno datano data

1.4yrs

Average Tenure

Experienced Management: 8F8's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jeppe Ovlesen
CEO & Directorless than a yearSEK 3.66m0.033%
€ 13.6k
Sten Scheibye
Directorless than a yearno datano data
Vibeke Strand
Member of Clinical Advisory Boardless than a yearno datano data
Mauro Perretti
Member of Scientific Advisory Boardno datano datano data
Anders Kronborg
Chairman of Boardless than a yearno datano data
Sten Sorensen
Directorless than a yearno datano data
Ravi Rao
Member of Clinical Advisory Boardless than a yearno datano data
Roy Fleischmann
Member of Clinical Advisory Boardless than a yearno datano data
Mauro Teixeira
Member of Scientific Advisory Boardno datano datano data

0.7yrs

Average Tenure

62yo

Average Age

Experienced Board: 8F8's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.